Senseonics stock trades at EUR 7.73 after Freedom study launch

Senseonics stock traded at 7.73 euros on Lang & Schwarz at 22:29 CET on Friday, November 6, 2026. The company had announced the start of a first-in-human study for its Freedom continuous glucose monitoring system on October 26.

Senseonics said in its investor relations update that Freedom is designed to be the world's first continuous glucose monitoring system without an on-body component. The study marks an early development step for a product intended to expand the company's implantable monitoring platform.

Implantable monitoring remains central

Senseonics develops and commercializes long-term implantable continuous glucose monitoring systems for people with diabetes. Its Eversense and Eversense XL systems combine an under-the-skin sensor with a removable and rechargeable smart transmitter and an app for real-time monitoring.

The company says Eversense and Eversense XL are designed for monitoring periods of up to 90 and 180 days, respectively. That product duration contrasts with the seven-to-14-day periods cited for non-implantable continuous glucose monitoring systems.

For investors, the Freedom program adds a product-development milestone to the existing Eversense platform. The next key questions are the study's progress and the company's ability to translate the design into a commercially viable system.

Senseonics stock traded at 7.73 euros on Lang & Schwarz at 22:29 CET on Friday, November 6, 2026. The real-time quote of Senseonics stock is available for monitoring.

Broader market developments can be followed in current S&P 500 market reports.

More news and analyses are available on Senseonics stock.